Objective: The objective of this study was to investigate the potential pleiotropic effects of rosuvastatin (RSV) in the left ventricular (LV) myocardium of dogs with moderate heart failure (HF). Methods: LV tissue was obtained from HF dogs randomized to 3 months therapy with low-dose RSV (n = 7), high-dose RSV (n = 7) or to no therapy (Control, n = 7) and from 7 normal dogs. mRNA and protein expression of prohypertrophic mediator NGFI-A binding protein 1 (Nab1), phosphatase and tensin homolog (PTEN), phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) were measured, as well as that of proinflammatory cytokine interleukin-6 (IL-6), bone marrow-derived stem cell markers cKit and Sca1, vascular endothelial and fibroblast growth factors (VEGF and FGF) and nitric oxide synthase (NOS) isoforms. Results: Nab1, PTEN, PI3K, mTOR and IL-6 increased in the controls. High-dose RSV reduced expression of Nab1, PTEN, PI3K, mTOR and IL-6 to near-normal levels. cKit and Sca1 significantly increased, while VEGF and FGF decreased in the controls compared to the normal dogs. RSV therapy further increased expression of cKit, Sca1, VEGF and FGF. High-dose RSV normalized the expression of NOS isoforms. Conclusion: These pleiotropic effects of RSV may account, in part, for the observed beneficial effect of RSV on LV function and structural remodeling.

Keywords:
Rosuvastatin, Heart failure, Left ventricular myocardium
1.
Baigent C, Keech A, Kearney PM, et al, Cholesterol Treatment Trialists’ Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
2.
Ramasubbu K, Estep J, White DL, Deswal A, Mann DL: Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415–426.
3.
Zacà V, Rastogi S, Imai M, et al: Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007;50:551–557.
4.
Kureishi Y, Luo Z, Shiojima I, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004–1010.
5.
Dimmeler S, Aicher A, Vasa M, et al: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391–397.
6.
Llevadot J, Murasawa S, Kureishi Y, et al: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399–405.
7.
Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–2261.
8.
Tavazzi L, Maggioni AP, Marchioli R, et al: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231–1239.
9.
Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al: Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009;10:1708–1716.
10.
Erbs S, Beck EB, Linke A, et al: High-dose rosuvastatin in chronic heart failure promotes vasculogenesis, corrects endothelial function, and improves cardiac remodeling – results from a randomized, double-blind, and placebo-controlled study. Int J Cardiol 2011;146:56–63.
11.
Sabbah HN, Stein PD, Kono T, et al: A canine model of chronic heart failure produced by multiple sequential intracoronary microembolization. Am J Physiol 1991;260:H1379–H1384.
12.
No authors listed. Position of the American Heart Association on Research Animal Use. Circulation 1985;71:849A–850A.
13.
Rastogi S, Imai M, Sharov VG, Mishra S, Sabbah HN: Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure. Am J Physiol Heart Circ Physiol 2008;295:H2475–H2482.
14.
Rastogi S, Sharov VG, Mishra S, et al: Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008;295:H2149–H2155.
15.
van der Harst P, Voors AA, van Gilst WH, Böhm M, van Veldhuisen DJ: Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 2006;71:443–454.
16.
Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH: The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004;37:449–471.
17.
Oudit GY, Penninger JM: Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 2009;82:250–260.
18.
Mann DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988–998.
19.
Asahara T, Masuda H, Takahashi T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221–228.
20.
Umar S, van der Laarse A: Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010;333:191–201.
21.
Jessup M, Brozena S: Heart failure. N Engl J Med 2003;348:2007–2018.
22.
Liao JK: Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 2004;52:248–253.
23.
Laufs U, Kilter H, Konkol C, Wassmann S, Bohm M, Nickenig G: Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002;53:911–920.
24.
Buitrago M, Lorenz K, Maass AH, et al: The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med 2005;11:837–844.
25.
Sugden PH: Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 2003;93:1179–1192.
26.
Baba HA, Stypmann J, Grabellus F, et al: Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res 2003;59:390–399.
27.
Haq S, Choukroun G, Lim H, et al: Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670–677.
28.
Buss SJ, Muenz S, Riffel JH, et al: Beneficial effects of mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 2009;54:2435–2446.
29.
Sola S, Mir MQS, Lerakis S, Tandon N, Khan BV: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332–337.
30.
Tousoulis D, Antoniades C, Bosinaku E, et al: Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359–363.
31.
Mozaffarian D, Minami E, Letterer RA, Lawler RL, McDonald GB, Levy WC: The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005;96:1699–1704.
32.
Pacher P, Schulz R, Liaudet L, et al: Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci 2005;26:302–310.
33.
Takimoto E, Kass DA: Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007;49:241–248.
34.
Ferrari R, Agnoletti L, Comini L, et al: Oxidative stress during myocardial ischaemia and heart failure. Eur Heart J 1998;19(suppl B):B2–B11.
35.
Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281–287.
36.
Landmesser U, Engberding N, Bahlmann FH, et al: Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933–1939.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.